CLINICAL_TRIALS
trial_result
· 2021-12-09
Clinical Trial Update: Dysport in Vulvodynia Phase II Study [Phase 2]
Summary
A Phase 2 study of Dysport (abobotulinumtoxinA) for vulvodynia was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Vulvodynia | Phase 2 | Status: TERMINATED | Results posted: 2021-12-09